Cannabinoid derivatives for treating autism spectrum disorder

Novel cannabinoid derivatives address the inadequacies in ASD treatments by improving anxiety and social interactions, offering a promising therapeutic approach for autism spectrum disorder and associated disorders.

WO2024231543A1PCT designated stage expired Publication Date: 2024-11-14GB LAB
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/062938
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for autism spectrum disorder (ASD) and associated disorders are inadequate, lacking a designated effective treatment that improves core symptoms and co-morbidities for all patients, particularly in reducing anxiety and enhancing social interactions.

Method used

Development of novel cannabinoid derivatives, specifically compounds of formula (I) and their pharmaceutical compositions, which are used to treat ASD and associated disorders by improving anxiety and social interaction symptoms.

Benefits of technology

The novel cannabinoid derivatives effectively reduce anxiety and improve social interactions in individuals with ASD and associated disorders without negatively impacting motor skills, development, or weight, demonstrating therapeutic potential as valuable therapeutic tools.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000007_0001
    Figure IMGF000007_0001
Patent Text Reader

Abstract

The present invention relates to novel cannabinoid derivatives for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders (such as behavior / impairments associated with autism; attention deficit with and without hyperactivity disorder associated with autism and intellectual disability associated with autism).
Need to check novelty before this filing date? Find Prior Art

Description

CANNABINOID DERIVATIVES FOR TREATING AUTISM SPECTRUM DISORDERFIELD OF INVENTION

[0001] The present invention relates to novel cannabinoid derivatives for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders (such as behavior / impairments associated with autism; attention deficit with and without hyperactivity disorder associated with autism and intellectual disability associated with autism).BACKGROUND OF INVENTION

[0002] Autism spectrum disorder (ASD) is a neurodevelopmental disease with a wide spectrum of manifestations. The description of the main features of ASD as being persistent deficits in social communication, and restricted and repetitive patterns of behavior, interests, or activities has not changed significantly since its original definition 80 years ago. However, different conditions, such as Asperger's syndrome, Rett syndrome, childhood disintegrative disorder, Kanner's syndrome, and pervasive developmental disorder, previously considered as distinct, are now included in autism spectrum disorder, which is broken into 3 levels. To be more precise, there are three levels of autism spectrum disorder (ASD), which are described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The three functional level of autism are: Level 1 « Requires support », Level 2 « Requires susbtancial support » and Level 3 « Requires very substantial support ». The three levels can be used as a springboard to better understand that autistic people have a variety of presentations. The three levels of ASD help medical providers prescribe appropriate therapies based on a person's unique needs. These therapies can help the person with ASD make the most of their strengths and improve their social, language, and occupational skills.

[0003] ASD can affect individuals along a continuum of severity; thus, each subject with ASD is susceptible to have a unique pattern of behavior and level of severity, from lowfunctioning to high functioning. However, the disorder is characterized by main features affecting all individuals in two areas: social communication and restricted, repetitive sensory-motor behaviors. The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, published in 2013, has now based the ASD spectrum on these two domains ( / '.<?., social communication, and restricted, repetitive, or unusual sensory-motor behaviors).

[0004] ASD results from early altered brain development and neural reorganization. Yet, the cause of ASD is unknown. But because of the complexity of the disorder, and the fact that symptoms and severity vary, both genetic and environmental factors may play a role in the disease’s onset. ASD symptoms generally appear in the first two years of life and can last throughout a person’s life, although symptoms may improve over time. Most adults suffering from ASD will not work full-time or live independently and many individuals with ASD require lifelong support of some kind.

[0005] Despite the high prevalence and the great social impact of ASD, there is currently no cure. In addition, there is still no designated effective treatment suitable to all patients for the core symptoms and co-morbidities of ASD. The goal of the treatments offered at the moment is to maximize the subject’s ability to function by reducing ASD symptoms and supporting development and learning. Therefore, current ASD treatment options include: behavior and communication therapies, educational therapies, family therapies, speech therapies, occupational therapies, physical therapies, and specific medications helping to control ASD symptoms (such as antipsychotic drugs or antidepressants).

[0006] Therefore, there is still an unmet need for an efficient treatment for ASD and / or associated disorders, in particular a treatment that could improve ASD symptoms for each and every individual suffering from ASD and / or associated disorders.

[0007] Consequently, the inventors herein disclose novel cannabinoid derivatives which would be valuable therapeutic tools for the treatment of autism spectrum disorder and / or associated disorders. In particular, the inventors surprisingly demonstrate that the compounds according to the invention are able to improve two important symptoms of ASD and / or associated disorders: anxiety and social interactions.SUMMARY

[0008] The present invention relates to a compound of formula (I):or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof, whereinRxis C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;R2is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, cyano, heterocyclyl, O-heterocyclyl, amino, or amido;R3is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, alkoxy, aryloxy, amino, amido, or C(O)ORawherein Rais H, deuterium, or C1-C4 alkyl;R4is H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, or unsubstituted C(O)Ci-C4alkyl;R5is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, or C(O)ORbwherein Rbis H, deuterium, or C1-C4 alkyl; and the dotted line represents an optional second carbon-carbon bond, wherein each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated, for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders (such as behavior / impairments associated with autism; attention deficit with and without hyperactivity disorder associated with autism and intellectual disability associated with autism).

[0009] In some embodiments, the compound of formula (I) is selected from compounds 1-38 delineated in Table A and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:[Table A]

[0010] In some embodiments, the compound of formula (I) is selected from compounds 1, 2, 3, 4, 7, 12 and 38, delineated in Table B and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:

[0011] Preferably, the compound (I) for use according to the invention is the compound38 of formula:(Compound 38) or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof.

[0012] The invention further relates to a pharmaceutical composition comprising a compound of formula (I):or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof, whereinR1is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;R2is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, cyano, heterocyclyl, O-heterocyclyl, amino, or amido;R3is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, alkoxy, aryloxy, amino, amido, or C(O)ORawherein Rais H, deuterium, or C1-C4 alkyl;R4is H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, or unsubstituted C(O)Ci-C4alkyl;R5is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, or C(O)ORbwherein Rbis H, deuterium, or C1-C4 alkyl; and the dotted line represents an optional second carbon-carbon bond, wherein each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated, and a pharmaceutical acceptable carrier or excipient, for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders.

[0013] In some embodiments, the pharmaceutical composition for use according to the invention comprises the compound of formula (I) selected from compounds 1-38 delineated in Table A and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof: [Table A]

[0014] The pharmaceutical composition for use can preferably comprise the compound of formula (I) selected from compounds 1, 2, 3, 4, 7, 12 and 38, delineated in Table B and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:

[0015] Preferably, the pharmaceutical composition for use according to the invention comprises Compound 38 of formula:(Compound 38) or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof.

[0016] With respect to the compound for use or the pharmaceutical composition for use according to the invention, the treatment of ASD can correspond to the treatment of anxiety and / or inappropriate social interactions.

[0017] Preferably, the associated disorders can be selected from behavior / impairments associated with autism, attention deficit with and without hyperactivity disorder associated with autism and / or intellectual disability associated with autism.DEFINITIONS

[0018] In the present invention, the following terms have the following meanings:Chemical Definitions

[0019] An “alkyl” group refers to any unsubstituted or substituted alkyl. An “unsubstituted alkyl” group refers to a saturated aliphatic hydrocarbon, including straightchain, branched-chain and cyclic alkyl groups. In some embodiments, the alkyl group has 1-12 carbons designated herein as C1-C12 alkyl. In some embodiments, the alkyl group has 1-6 carbons designated herein as Ci-Ce alkyl. In some embodiments, the alkyl group has 1-4 carbons designated here in as C1-C4 alkyl. A “substituted alkyl” group refers to an alkyl which is substituted by one or more groups selected from halogen, hydroxyl, aryl, heterocyclyl, amino and amido. Non-limiting examples of alkylsubstituents include benzyl, 1 -phenylethyl, 2-(dimethylamino)-ethyl, 3-(morpholino)- propyl, and 2-hydroxyethyl.

[0020] An “alkenyl” group refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond including straight-chain, branched-chain and cyclic alkenyl groups. In one embodiment, the alkenyl group has 2-12 carbon atoms designated here as C2-C12 alkenyl. In another embodiment, the alkenyl group has 2-6 carbon atoms in the chain designated here as C2-C6 alkenyl. Exemplary alkenyl groups include ethenyl, propenyl, nbutenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl and decenyl. The alkenyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.

[0021] An “alkynyl” group refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond including straight-chain and branched-chain. In some embodiments, the alkynyl group has 2-12 carbon atoms in the chain designated here as C2-C12 alkynyl. In some embodiments, the alkynyl group has 2-6 carbon atoms in the chain designated here as C2-C6 alkynyl. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, heptynyl, octynyl and decynyl. The alkynyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.

[0022] The term “aryl” used herein alone or as part of another group refers to an aromatic ring system containing from 6 to 14 ring carbon atoms. The aryl ring can be a monocyclic, bicyclic, tricyclic and the like. Non-limiting examples of aryl groups are phenyl, naphthyl including 1 -naphthyl and 2-naphthyl, and the like. The aryl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.

[0001] The term “heterocyclic ring” or “heterocyclyl” used herein alone or as part of another group refers to five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and / or nitrogen, in particular oxygen, as a ring atom. These five-membered to eight-membered rings can be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Exemplary heterocyclicrings include piperidinyl, pyrrolidinyl pyrrolinyl, pyrazolinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, dihydropyranyl, tetrahydropyranyl, dihydrothiazolyl, glucosyl, and the like. The heterocyclyl group can be unsubstituted or substituted through available atoms with one or more groups defined hereinabove for alkyl. It is to be understood that “O-heterocyclyl” includes an oxygen linked to a heterocyclyl group as defined hereinabove. An exemplary O-heterocyclyl includes, but is not limited to, O-glycosyl.

[0002] The term “acyl” as used herein encompasses groups such as, but not limited to, formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, benzoyl and the like. In some embodiments, the acyl is an unsubstituted C(O)Ci-C4 alkyl. In some embodiments, the acyl is other than C(O)CF3.

[0003] A “hydroxy” group refers to an -OH group.

[0004] An “alkoxy” group refers to an -O-alkyl group wherein alkyl is as defined above. Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, benzyloxy, and the like.

[0005] An “aryloxy” group refers to an -O-aryl group wherein aryl is as defined above. Exemplary aryloxy groups include, but are not limited to, phenyloxy, and the like.

[0006] An “amino” group refers to an -NH2 group, an -NHR group, or an -NRR’ group, wherein R and R’ are each independently alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylamino, or alkyl-heterocyclyl as defined above.

[0007] An “amido” group refers to a -C(O)NH2 group, -C(O)NHR group, or a - C(O)NRR’ group wherein R and R’ are each independently unsubstituted or substituted alkyl (including alkyl-amino, or alkyl-heterocyclyl), alkenyl, alkynyl, aryl, or heterocyclyl, as defined above.

[0008] “Halogen” or “halo” refers to chlorine, bromine fluorine, and iodine.

[0009] “Haloalkyl” refers to an alkyl group having some or all of the hydrogens independently replaced by a halogen. Exemplary haloalkyls include, but are not limited to, trichloromethyl, tribromomethyl, trifluoromethyl, triiodomethyl, difluoromethyl, chlorodifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl bromomethyl, chloromethyl, fluoromethyl, iodomethyl, and the like.

[0010] A “nitro” group refers to an -NO2 group.

[0011] A “cyano” group refers to a -CN group.

[0012] The term “organic or inorganic cation” refers to counter-ions for the carboxylate anion of a carboxylate salt. The counter-ions are chosen from the alkali and alkaline earth metals (such as lithium, sodium, potassium, barium, aluminum and calcium); ammonium and mono-, di- and tri-alkyl amines such as trimethylamine, cyclohexylamine; and the organic cations, such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations. Other cations encompassed by the above term include the protonated form of procaine, quinine and N-methylglucos amine. Furthermore, any zwitterionic form of the instant compounds formed by a carboxylic acid and an amino group are also contemplated.

[0013] “Optionally deuterated” as used herein refers to a group that can be unsubstituted or substituted with at least one deuterium, i.e., one or more hydrogens can be replaced by one or more deuterons. In some embodiments, all hydrogens in the group are replaced by deuterons.

[0014] The term “compound” is defined herein to include pharmaceutically acceptable salts, solvates, hydrates, polymorphs, enantiomers, diastereoisomers, racemates and the like of the compounds having a formula as set forth herein.

[0015] “Cx-Cy” or “(Cx-Cy)” preceding the name of a group means that the group comprises from x to y carbon atoms, in accordance to common terminology in the chemistry field.

[0016] The term “salt” as used herein encompasses both base and acid addition salts including, but not limited to, carboxylate salts or salts with amine nitrogens, and include salts formed with the organic and inorganic anions and cations detailed below. Further encompassed by the term are salts formed by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include hydrochloric, hydrofluoric, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and the like.

[0017] “Solvate” means a physical association of a compound as described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates and the like.

[0018] “Hydrate” refers to a solvate wherein the solvent molecule is water (H2O).

[0019] “Polymorph” refers to a particular crystalline state of a substance, which can be characterized by particular physical properties such as X-ray diffraction, IR spectra, melting point, and the like.General Definitions

[0020] As used herein, the use of “a” and “an” means “at least one” or “one or more” unless the context clearly dictates otherwise. It should be noted that the term “and” or the term “or” are generally employed in their sense including “and / or” unless the context clearly dictates otherwise.

[0021] “About” is used herein to mean approximately, roughly, around, or in the region of. The term “about” preceding a figure means plus or less 10 % of the value of the figure. When the term “about” is used in conjunction with a numerical range, it modifies thatrange by extending the boundaries above and below the numerical values set forth by 10%.

[0022] “Administration”, or a variant thereof (e.g. , “administering”), means providing a therapeutic agent (e.g., a compound as described herein) alone or as part of a pharmaceutically acceptable composition, to a subject, in particular to the patient in whom / which the condition, symptom, or disease is to be treated.

[0023] “Comprise” or a variant thereof (e.g. , “comprises”, “comprising”) is used herein according to common patent application drafting terminology. Hence, “comprise” preceded by an object and followed by a constituent means that the presence of a constituent in the object is required (typically as a component of a composition), but without excluding the presence of any further constituent(s) in the object. Moreover, any occurrence of “comprise” or a variant thereof herein also encompasses narrower expression “substantially consist of’, further narrower expression “consist of’ and any variants thereof (e.g., “consists of’, “consisting of’), and may be replaced thereby, unless otherwise stated.

[0024] “Human” refers to a male or female human subject at any stage of development, including neonate, infant, juvenile, adolescent and adult.

[0025] “Pharmaceutically acceptable” means that the ingredients of a composition are compatible with each other and not deleterious to the patient to which / whom it is administered.

[0026] “Pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” refers to an excipient or carrier that does not produce an adverse, allergic or other untoward reaction when administered to a mammal, preferably a human. It includes any and all solvents, such as, for example, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents. A pharmaceutically acceptable excipient or carrier refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. For human administration, preparations should meet sterility, pyrogenicity, generalsafety and purity standards as required by the regulatory offices such as the FDA (US Food and Drug Administration) or EMA (European Medicines Agency).

[0027] “Selected from” is used herein according to common patent application drafting terminology, to introduce a list of elements among which one or more item(s) is (are) selected. Any occurrence of “selected from” in the specification may be replaced by “selected from the group comprising or consisting of’ and reciprocally without changing the meaning thereof.

[0028] “Subject” refers to a warm-blooded animal, more preferably a mammal. The term “mammal” refers here to any mammal, including humans. Preferably, the mammal is a primate, more preferably a human. In some embodiments, a subject may be a “patient” as defined herein, who / which is awaiting the receipt of, or is receiving medical care or was / is / will be the object of a medical procedure, or is monitored for the development of the targeted disease or condition. In some embodiments, the subject is an adult (for example a subject above the age of 18). In some embodiments, the subject is a child (for example a subject below the age of 18). In some embodiments, the subject is a male. In some embodiments, the subject is a female.

[0029] “Therapeutically effective amount” (in short “effective amount”) refers to the amount of a therapeutic agent (e.g., a compound as described herein) that is sufficient to achieve the desired therapeutic, prophylactic or preventative effect in the patient to which / whom it is administered, without causing significant negative or adverse side effects to said patient. A therapeutically effective amount may be administered prior to the onset of the disease, disorder, or condition, for a prophylactic or preventive action. Alternatively, or additionally, the therapeutically effective amount may be administered after initiation of the disease, disorder, or condition, for a therapeutic action.

[0030] The terms “treating” or “treatment” or “alleviation” refer to a therapeutic (or curative) treatment, to a prophylactic (or preventive) treatment, or to both a therapeutic (or curative) treatment and a prophylactic (or preventive) treatment; wherein the object is to prevent, reduce, alleviate, and / or slow down (lessen) one or more symptoms of autism spectrum disorder (ASD) in a subject in need thereof. Symptoms of ASD include, withoutbeing limited to, abnormal body posturing or facial expressions, abnormal tone of voice, aggressiveness, anxiety, attention deficit, avoidance of eye contact or poor eye contact, behavioral disturbances, behavior impairments, deficits in language comprehension, delay in learning to speak, flat or monotonous speech, hyperactivity disorder, inappropriate social interaction, intellectual disabilities, intense focus on one topic, lack of empathy, lack of understanding social cues, learning disability or difficulty, not engaging in play with peers, persistent deficits in social communication, preoccupation with specific topics, problems with two-way conversation, repeating words or phrases, repetitive movements, self-abusive behaviors, sleep disturbances, social withdrawal, unusual reactions in social settings, using odd words or phrases, loss of language skills, trouble communicating, trouble adjusting to social situations, restricted and repetitive patterns of behavior, interests, or activities. In some embodiments, “treating” or“treatment” refers to a therapeutic treatment. In some embodiments, “treating” or“treatment” refers to a prophylactic or preventive treatment. In some embodiments,“treating” or “treatment” refers to both a prophylactic (or preventive) treatment and a therapeutic treatment. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully “treated” for a disease or condition if, after receiving a therapeutic amount of a therapeutic agent, the patient shows observable and / or measurable reduction in or absence of one or more of the following: relief to some extent, of one or more of the symptoms associated with ASD; reduced morbidity and mortality, and improvement in quality-of-life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.DETAILED DESCRIPTION

[0031] The present invention relates to novel cannabinoid derivatives for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders.

[0032] In some embodiments, the compound of the present invention is represented by the structure of formula (I):or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof, whereinR1is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;R2is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, cyano, heterocyclyl, O-heterocyclyl, amino, or amido;R3is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, alkoxy, aryloxy, amino, amido, or C(O)ORawherein Rais H, deuterium, or C1-C4 alkyl;R4is H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, acyl, or unsubstituted C(O)Ci-C4 alkyl;R5is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, or C(O)ORbwherein Rbis H, deuterium, or C1-C4 alkyl; and the dotted line represents an optional second carbon-carbon bond, wherein each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated.

[0033] In some embodiments, in formula (I), R1is C1-C12 alkyl, preferably C1-C10 alkyl. In some embodiments, R1is selected from propyl, butyl, pentyl, hexyl, heptyl, octyl, 1,1- dimethyl pentyl, 1 -methyl pentyl, 1 -methyl heptyl, 1,1 -dimethyl heptyl, and 1 -phenyl ethyl.

[0034] In some embodiments, in formula (I), R2is hydrogen. In some embodiments, in formula (I), R2is halogen, preferably fluorine. In some embodiments, in formula (I), R2is hydroxyl. In some embodiments, in formula (I), R2is nitro. In some embodiments, in formula (I), R2is cyano. In some embodiments, in formula (I), R2is a heterocyclylselected from 4-morpholinyl, and 1-piperazinyl. In some embodiments, in formula (I), R2is O-heterocyclyl, preferably O-glucosyl.

[0035] In some embodiments, in formula (I), R3is hydrogen. In some embodiments, in formula (I), R3is halogen, preferably fluorine. In some embodiments, in formula (I), R3is hydroxyl. In some embodiments, in formula (I), R3is alkoxy selected from methoxy, ethoxy and benzyloxy. In some embodiments, in formula (I), R3is C(O)OH. In some embodiments, in formula (I), R3is C(O)OCH3 or C(O)OCD3. In some embodiments, in formula (I), R3is a -C(O)NHRCamido, wherein Rcis an alkyl-amino or an alkyl- heterocyclyl.

[0036] In some embodiments, in formula (I), R4is hydrogen. In some embodiments, in formula (I), R4is Ci-Ce alkyl. In some embodiments, in formula (I), R4is hydroxyethyl, preferably 2-hydroxyethyl. In some embodiments, in formula (I), R4is aryl, preferably benzyl.

[0037] In some embodiments, in formula (I), R5is C1-C4 alkyl. In some embodiments, in formula (I), R5is methyl. In some embodiments, in formula (I), R5is hydroxymethyl. In some embodiments, in formula (I), R5is C(O)OH.

[0038] In some embodiments, the dotted line is absent. In some embodiments, the dotted line represents a second carbon-carbon bond.

[0039] In some embodiments, the dotted line is absent and the ring is a cyclohexyl ring. In some embodiments, the dotted line represents a second carbon-carbon bond and the ring is a cyclohexenyl ring.

[0040] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is halogen, R5is methyl, and the dotted line represents a second carbon-carbon bond. In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is fluorine, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0041] In some embodiments, in formula (I), R1is propyl, R2, R3, and R4are each H, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0042] In some embodiments, in formula (I), R1is hexyl, R2, R3, and R4are each H, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0043] In some embodiments, in formula (I), R1is heptyl, R2, R3, and R4are each H, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0044] In some embodiments, in formula (I), R1is 1,1-dimethyl heptyl, R2, R3, and R4are each H, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0045] In some embodiments, in formula (I), R1is pentyl, R2is fluorine, R3and R4are each H, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0046] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is C(O)OH, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0047] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is C(O)OCH3, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0048] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is C(O)OCDs, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0049] In some embodiments, in formula (I), R1is pentyl, R2, R3, and R4are each H, R5is methyl, and the dotted line is absent.

[0050] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is a -C(O)NHRCamido, wherein Rcis -ethyldimethylamino, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0051] In some embodiments, in formula (I), R1is pentyl, R2and R4are each H, R3is a -C(O)NHRCamido, wherein Rcis -propylmorpholino, R5is methyl, and the dotted line represents a second carbon-carbon bond.

[0052] In some embodiments, the compound of the present invention is represented by the structure of formula (I) as described above, with the proviso that when R2, R3, and R4are H, R5is methyl, and the dotted line represents a second carbon-carbon bond, then R1is not n-pentyl or 2-phenylethyl.

[0053] In some embodiments, the compound of the present invention is represented by the structure of formula (I) as described above, with the proviso that when R2, R3, and R4are H, R5is methyl, and the dotted line represents a second carbon-carbon bond, then R1is not a straight-chain, unsubstituted C5H11 alkyl, i.e., n-pentyl.

[0054] In some embodiments, the compound of the present invention is represented by the structure of formula (I) as described above, with the proviso that when R2, R3, and R4are H, R5is methyl, and the dotted line represents a second carbon-carbon bond, then R1is not 2-phenylethyl.

[0055] It is to be understood for all compounds encompassed by the structure of formula (I), that when R2, R3, and R4are H, R5is methyl, and the dotted line represents a second carbon-carbon bond, then R1is not a straight-chain, unsubstituted C5H11 alkyl, i.e., n-pentyl. It is further to be understood for all compounds encompassed by the structure of formula (I), that when R2, R3, and R4are H, R5is methyl, and the dotted line represents a second carbon-carbon bond, then R1is not 2-phenylethyl, i.e., 2 -phenyl- 1 -ethyl.

[0056] Representative and non-limiting examples of such structures are compounds selected from compounds 1-38.

[0057] In some embodiments, the compound of formula (I) is selected from compounds 1-38 of Table A below, or salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.[Table A]

[0058] In some embodiments, the compound of formula (I) is selected from compounds 1, 2, 3, 4, 7, 12 and 38, delineated in Table B and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:[Table B]

[0059] In some embodiments, the compound of formula (I) is compound 38 as defined above, or salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof. Compound 38 can also be referred to as 331-18A:(Compound 38; 331-18A)

[0060] As used herein “331-18A” refers to a phytocannabinoid, i.e., a bioactive compound of the Cannabis plant, identified in decarboxylated CBD-rich extracts of the Cannabis plant. Compound 331-18A can also be referred to as Compound 38, 6,12-dihydro-6-hydroxy-cannabidiol, or l,3-dihydro-2-[6-(l-hydroxy-l-methyl-ethyl)- 3-methyl-2-cyclohexene-l-yl]-5-pentyl-benzene, and is registered under CAS number 66052-28-6. Compound 38 was first described in EP 0494 665 B l, US 5,227,537 and Stoss and Merrath (Synlett, 1991, 1991(8): 553-554).

[0061] All references herein to a compound as described herein (e.g., compound of formula (I), compounds 1-38) include references to salts, solvates, multi component complexes and liquid crystals thereof. All references herein to a compound as described herein include references to polymorphs and crystal habits thereof. All references herein to a compound as described herein include references to isotopically-labelled compounds thereof, including deuterated compounds thereof. All references herein to a compound as described herein include references to stereoisomers thereof either in admixture or in pure or substantially pure form. These compounds can have asymmetric centers at one or more atoms. Consequently, the compounds can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The present invention contemplates the use of any racemates (z.e., mixtures containing equal amounts of each enantiomer), enantiomerically enriched mixtures (z.e., mixtures enriched for one enantiomer), pure enantiomers or diastereomers, or any mixtures thereof. The chiral centers can be designated as R or S or R,S or d,D, 1,L or d,l, D,L. Where compounds as described herein contain a double bond (for example where R1is a C2-C12 alkenyl), it is to be understood that it encompasses all structural and geometrical isomers including cis, trans, E and Z isomers and optical isomers, independently at each occurrence.

[0062] The preparation of the compounds as described therein may be accomplished using procedures well known to those skilled in the art. Moreover, the process of preparation of the compounds is exemplified in Example 1 (compound synthesis).

[0063] Another object of the present invention is a composition comprising, consisting essentially of or consisting of at least one compound as described herein.

[0064] As used herein, “consisting essentially of’, with reference to a composition, means that the at least one compound as described herein is the only one therapeutic agent or agent with a biologic activity within said composition.

[0065] In some embodiments, said composition is a pharmaceutical composition and further comprises at least one pharmaceutically acceptable carrier or excipient.

[0066] Therefore, another object of the present invention is a pharmaceutical composition comprising, consisting essentially of or consisting of at least one compound as described herein, and at least one pharmaceutically acceptable carrier or excipient.

[0067] In some embodiments, the pharmaceutical composition comprises at least one compound as described herein as the sole active ingredient.

[0068] In some embodiments, the pharmaceutical composition further comprises at least another therapeutic agent. In some embodiments, the pharmaceutical composition comprises at least one compound as described herein in combination with one or more cannabinoids, terpenes, terpenoids, flavonoids, oils, nitrogenous compounds, amino acids, proteins, glycoproteins, sugars, hydrocarbons, fatty acids, esters, lactones, steroids, non-cannabinoid phenols, and a mixture or combination thereof. In some embodiments, the pharmaceutical composition comprises at least one compound as described herein in combination with at least another compound as described herein.

[0069] Suitable pharmaceutically acceptable carriers or excipients include, but are not limited to, a binder, a filler, a diluent, a surfactant or emulsifier, a glidant or lubricant, a buffering or pH adjusting agent, a tonicity enhancing agent, a wetting agent, a chelating agent, a preservative, an antioxidant, a flavoring agent, a colorant, and a mixture or combination thereof. In some embodiments, the pharmaceutically acceptable carrier is a lipid carrier.

[0070] Suitable binders include, but are not limited to, polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose, starch, and gelatin.

[0071] Suitable fillers include, but are not limited to, sugars such as lactose, sucrose, mannitol or sorbitol and derivatives thereof (e.g., amino sugars), ethylcellulose, microcrystalline cellulose, and silicified microcrystalline cellulose.

[0072] Suitable lubricants include, but are not limited to, sodium stearyl fumarate, stearic acid, polyethylene glycol or stearates, such as magnesium stearate.

[0073] Suitable diluents include, but are not limited to, dicalcium phosphate dihydrate, sugars, lactose, calcium phosphate, cellulose, kaolin, mannitol, sodium chloride, starch, and various oils.

[0074] Suitable surfactants or emulsifiers include, but are not limited to, polyvinyl alcohol (PVA), polysorbate, polyethylene glycols, polyoxyethylene-polyoxypropylene, block copolymers known as “poloxamer”, polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid ester such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate (Tween), polyethylene glycol fatty acid ester such as polyoxyethylene monostearate, polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether, polyoxyethylene castor oil and hardened castor oil such as polyoxyethylene hardened castor oil, and lecithin.

[0075] Suitable glidants or lubricants include, but are not limited to, colloidal silicon dioxide, magnesium stearate, talc, and mineral oil.

[0076] Suitable buffering or pH adjusting agents include, but are not limited to, acidic buffering agents such as short chain fatty acids, citric acid, acetic acid, hydrochloric acid, sulfuric acid and fumaric acid; and basic buffering agents such as tris, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, and magnesium hydroxide.

[0077] Suitable tonicity enhancing agents include, but are not limited to, ionic and nonionic agents such as, alkali metal or alkaline earth metal halides, urea, glycerol, sorbitol, mannitol, propylene glycol, and dextrose.

[0078] Suitable wetting agents include, but are not limited to, glycerin, cetyl alcohol, and glycerol mono stearate.

[0079] Suitable chelating agents include, but are not limited to, modified or unmodified cyclodextrin (e.g., a-cyclodextrin, P -cyclodextrin, y-cyclodextrin, 2-hydroxypropyl-P- cyclodextrin, methyl-P-cyclodextrin), dextrin, maltodextrin, and a mixture or combination thereof.

[0080] Suitable preservatives include, but are not limited to, benzalkonium chloride, benzoxonium chloride, thiomersal, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric borate, methylparaben, propylparaben, chlorobutanol, benzyl alcohol, phenyl alcohol, chlorohexidine, and polyhexamethylene biguanide.

[0081] Suitable antioxidants include, but are not limited to, sorbic acid, ascorbic acid, ascorbate, glycine, a-tocopherol, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT).

[0082] Suitable flavoring agents include, but are not limited to, sweeteners such as sucralose and synthetic flavor oils and flavoring aromatics, natural oils, extracts from plants, leaves, flowers, and fruits, and combinations thereof. Exemplary flavoring agents include cinnamon oils, oil of wintergreen, peppermint oils, clover oil, hay oil, anise oil, eucalyptus, vanilla, citrus oil such as lemon oil, orange oil, grape and grapefruit oil, and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.

[0083] Suitable colorants include, but are not limited to, alumina (dried aluminum hydroxide), annatto extract, calcium carbonate, canthaxanthin, caramel, P-carotene, cochineal extract, carmine, potassium sodium copper chlorophyllin (chlorophyllin- copper complex), dihydroxyacetone, bismuth oxychloride, synthetic iron oxide, ferric ammonium ferrocyanide, ferric ferrocyanide, chromium hydroxide green, chromium oxide greens, guanine, mica-based pearlescent pigments, pyrophyllite, mica, dentifrices, talc, titanium dioxide, aluminum powder, bronze powder, copper powder, and zinc oxide.

[0084] Another object of the present invention is a medicament comprising, consisting essentially of or consisting of at least one compound as described herein.

[0085] The preparation of the pharmaceutical composition or the medicament as described therein may be accomplished using pharmaceutical procedures well known to those skilled in the art.

[0086] The invention further relates to at least one compound according to the invention, or at least one composition, pharmaceutical composition or medicament as describedherein for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders.

[0087] “Autism spectrum disorder” or “ASD” refers to a broad range of neurological and developmental disorders affecting how people interact with others, communicate, learn, and behave. ASD symptoms generally appear in the first two years of life and can last throughout a person’s life, although symptoms may improve over time. Each subject with ASD is susceptible to have a unique pattern of behavior and level of severity, however, the two main symptoms characterizing all subjects suffering from ASD are deficits in social communication and interaction skills, and restricted, repetitive, or unusual sensory-motor behaviors. To be more precise, there are three levels of autism spectrum disorder (ASD), which are described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The three functional level of autism are: Level 1 « Requires support », Level 2 « Requires susbtancial support » and Level 3 « Requires very substantial support ». The three levels can be used as a springboard to better understand that autistic people have a variety of presentations. The three levels of ASD help medical providers prescribe appropriate therapies based on a person's unique needs. These therapies can help the person with ASD make the most of their strengths and improve their social, language, and occupational skills.

[0088] “Associated disorders” refers to conditions associated with autism spectrum disorder, such as behavior / impairments associated with autism, attention deficit with and without hyperactivity disorder associated with autism and / or intellectual disability associated with autism.

[0089] The invention further relates to a method for treating autism spectrum disorder (ASD) and / or associated disorders in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound as described herein, or at least one composition, pharmaceutical composition or medicament as described herein.

[0090] Another object of the present invention is at least one compound, composition, pharmaceutical composition or medicament as described herein for treating or for use inthe treatment of autism spectrum disorder (ASD) and / or associated disorders in a subject in need thereof.

[0091] Another object of the present invention is a pharmaceutical composition for treating or for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders in a subject in need thereof, wherein said pharmaceutical composition comprises at least one compound as described herein.

[0092] Another object of the present invention is the use of at least one compound as described herein or a composition, pharmaceutical composition, or medicament as described herein, in the manufacture of a medicament for the treatment of autism spectrum disorder (ASD) and / or associated disorders in a subject in need thereof.

[0093] In some embodiments, the treatment of ASD corresponds to the treatment of at least one of the symptoms of ASD.

[0094] In some embodiments, the treatment of ASD associated disorders corresponds to the treatment of at least one of the symptoms of ASD associated disorders, such as the treatment of behavior / impairments associated with autism, attention deficit with and without hyperactivity disorder associated with autism and / or intellectual disability associated with autism.

[0095] Symptoms of ASD include, without being limited to, abnormal body posturing or facial expressions, abnormal tone of voice, aggressiveness, anxiety, attention deficit, avoidance of eye contact or poor eye contact, behavioral disturbances, behavior impairments, deficits in language comprehension, delay in learning to speak, flat or monotonous speech, hyperactivity disorder, inappropriate social interaction, intellectual disabilities, intense focus on one topic, lack of empathy, lack of understanding social cues, learning disability or difficulty, not engaging in play with peers, persistent deficits in social communication, preoccupation with specific topics, problems with two-way conversation, repeating words or phrases, repetitive movements, self-abusive behaviors, sleep disturbances, social withdrawal, unusual reactions in social settings, using odd words or phrases, loss of language skills, trouble communicating, trouble adjusting to social situations, restricted and repetitive patterns of behavior, interests, or activities.

[0096] In some embodiments, the treatment of ASD corresponds to the treatment of anxiety and / or inappropriate social interactions. In some embodiments, the treatment of ASD corresponds to the treatment of anxiety. In some embodiments, the treatment of ASD corresponds to the treatment of inappropriate social interactions. In some embodiments, the at least one compound, or the composition, pharmaceutical composition or medicament, as described herein, allows to decrease anxiety and / or inappropriate social interactions. In some embodiments, the at least one compound, or the composition, pharmaceutical composition or medicament, as described herein, allows to decrease anxiety.

[0097] In some embodiments, the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein does not affect the subject’s motor skills.

[0098] As used herein “does not affect the subject’s motor skills” means that after administration of the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein to the subject in need thereof, said subject’ s motor skills are not negatively impacted or diminished as compared to a reference subject. In some embodiments, a reference subject is a healthy subject, in particular a subject who does not need to be treated with the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein. In some embodiments, a reference subject is a subject affected with ASD and / or associated disorders who does not receive the least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein.

[0099] In some embodiments, the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein, does not affect the subject’s development and / or the subject’s growth. In some embodiments, the at least one compound as descried herein, or the composition, pharmaceutical composition or medicament as described herein, does not affect the subject’s weight.

[0100] As used herein “does not affect the subject’s development and / or the subject’s growth” or “does not affect the subject’s weight” means that after administration of the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein to the subject in need thereof, said subject’s development and / or growth is not negatively impacted or diminished, in particular, the subject does not lose or gain weight, as compared to a reference subject. In some embodiments, a reference subject is a healthy subject, in particular a subject who does not need to be treated with the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein. In some embodiments, a reference subject is a subject affected with ASD and / or associated disorders who does not receive the least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein.

[0101] In some embodiments, the at least one compound as descried herein, or the composition, pharmaceutical composition or medicament as described herein, does not affect the subject’s social behavior.

[0102] As used herein “does not affect the subject’s social behavior” means that after administration of the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein to the subject in need thereof, said subject’s social behavior is not negatively impacted or diminished, as compared to a reference subject. In some embodiments, a reference subject is a healthy subject, in particular a subject who does not need to be treated with the at least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein. In some embodiments, a reference subject is a subject affected with ASD and / or associated disorders who does not receive the least one compound as described herein, or the composition, pharmaceutical composition or medicament as described herein.

[0103] For use in administration to a subject, the at least one compound as described herein or the composition, pharmaceutical composition or medicament, as described herein, will be formulated.

[0104] In some embodiments, the at least one compound as described herein or the composition, pharmaceutical composition or medicament as described herein, is in a form selected from a tablet, an effervescent tablet, a pill, a capsule (e.g., soft or hard gelatin capsule, a hydroxypropyl methylcellulose (HPMC) capsule, a pullulan capsule), pellets, a strip, a caplet, granules, powder, effervescent powder, powder for suspension, a wafer, coated or uncoated beads, a lozenge, a sachet, a cachet, an elixir, an osmotic pump, a depot system, an iontophoretic system, a patch, a suspension, a dispersion, an emulsion, a solution, a syrup, an aerosol, an oil, an ointment, a suppository, a gel, a sublingual or buccal delivered form for local absorption, and a cream.

[0105] In some embodiments, the least one compound as described herein or the composition, pharmaceutical composition or medicament as described herein, is a lyophilized formulation.

[0106] For preparing solid compositions such as tablets, the active pharmaceutical ingredient is mixed with a pharmaceutical carrier or excipient to form a solid preformulation composition containing a substantially homogeneous distribution of the at least one compound as described herein in the pharmaceutical carrier or excipient.

[0107] Any method can be used to prepare the composition, pharmaceutical composition or medicament. For example, solid dosage forms can be prepared by wet granulation, dry granulation, direct compression and the like as is known in the art. The liquid forms in which the at least one compound as described herein may be incorporated, for administration via a route selected from oral, topical or by injection, include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0108] The composition, pharmaceutical composition or medicament as described herein may be formulated as a single-phase aqueous emulsion or multiple emulsions. In some embodiments, the composition, pharmaceutical composition or medicament is formulated as an emulsion. These emulsions may be oil-in-water (o / w) emulsions, water-in-oil (w / o) emulsions, or multiple emulsions such as oil-in- water- in-oil (o / w / o) orwater-in-oil-in-water (w / o / w) double emulsions. It is understood that the oil phase can comprise silicone oils, non-silicone organic oils, or mixtures thereof. The composition, pharmaceutical composition or medicament can comprise two immiscible phases that are reconstituted prior to use.

[0109] In some embodiments, the composition, pharmaceutical composition or medicament as described herein are liposomal composition, pharmaceutical composition or medicament comprising at least one compound represented by the structure of formula (I) or any of compounds 1-38 as defined herein encapsulated in a liposome comprising a lipid bilayer structure.

[0110] Another formulation encompassed by the present invention comprises transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the at least one compound as described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art.

[0111] In some embodiments, the composition, pharmaceutical composition or medicament is prepared for topical administration, e.g., as an oil, ointment, gel or cream. Adjuvants for topical administration may include, for example, sodium carboxymethylcellulose, poly acrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol and wood wax alcohols. The term “gel” as used herein, refers to a substantially dilute cross-linked system, which exhibits little or no flow when in the steady-state having a solid jelly-like matrix. As contemplated herein, gel may comprise hydrogel, organogel, thermosensitive gel, nonthermosensitive gel, and aerogel.

[0112] Compositions for inhalation or aspiration include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable carriers or excipients as described above. The compositions may be administered by the oral or nasal respiratory route. Compositions may also be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittentpositive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices (e.g., inhalers) that deliver the formulation in an appropriate manner.

[0113] The composition, pharmaceutical composition or medicament as described herein may exhibit release mode which may be immediate release, controlled release or a mixture thereof. “Immediate release” (IR) composition, pharmaceutical composition or medicament in the context according to the present invention refers to composition, pharmaceutical composition or medicament in which the active ingredient is released without delay following administration. “Controlled release” (CR) composition, pharmaceutical composition or medicament in the context according to the present invention refers to composition, pharmaceutical composition or medicament in which the active ingredient is released gradually over a period of time following administration.

[0114] In some embodiments, the at least one compound in the context of the invention or the composition, pharmaceutical composition or medicament as described herein, is formulated (or adapted) for administration via a route selected from buccal, oral, rectal, pulmonal, topical, transdermal, intra-arterial, intranasal, intraperitoneal, intramuscular, subcutaneous, intravenous, intra-alveolar, intra- articular, intra-synovial, intra- sternal, intrathecal, intrahepatic, intralesional and intracranial.

[0115] In some embodiments, the at least one compound of any of formulae (I) or 1-38 as described herein, or the composition, pharmaceutical composition or medicament as described herein, is to be administered to the subject in need thereof buccally, orally, rectally, nasally, pulmonary, topically, subcutaneously, intravenously, or intramuscularly.

[0116] In some embodiments, the at least one compound of any of formulae (I) or 1-38 as described herein, or the composition, pharmaceutical composition or medicament as described herein, is to be administered to the subject in need thereof in a therapeutically effective amount.

[0117] It will be however understood that the total daily usage of the at least one compound, composition, pharmaceutical composition or medicament as described hereinwill be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disease being treated and the severity of the disease; activity of the compound employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific therapeutic agent employed; the duration of the treatment; drugs used in combination or coincidental with the specific therapeutic agent employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. The total dose required for each treatment may be administered by multiple doses or in a single dose.

[0118] A preferred dosage will be within the range of about 0.01-1,000 mg / kg of body weight, about 0.1 mg / kg to 100 mg / kg, about 1 mg / kg to 100 mg / kg, about 10 mg / kg to 75 mg / kg, about 0.1 to 1 mg / kg etc., including each value within the specified ranges. Exemplary non-limiting amounts of the at least one compound of any of formulae (I) or 1-38 include about 0.1 mg / kg, about 0.2 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 20 mg / kg, about 50 mg / kg, about 60 mg / kg, about 75 mg / kg, and about 100 mg / kg. Alternatively, the amount administered can be measured and expressed as molarity of the administered compound. By way of illustration and not limitation, the at least one compound of any of formulae (I) or 1-38 can be administered in a range of about 0.1 to 10 mM, including each value within the specified range e.g., about 0.1, 0.25, 0.5, 1 or 2 mM. Alternatively, the amount administered can be measured and expressed as mg / ml, pg / ml, or ng / ml.

[0119] The administration schedule will depend on several factors such as the severity and progression of the disorder, age, weight etc. For example, the at least one compound of any of formulae (I) or 1-38 as described herein, or the composition, pharmaceutical composition or medicament as described herein, can be taken once-daily, twice-daily, thrice daily, once-weekly or once-monthly. In addition, the administration can be continuous, i.e., every day, or intermittent. The terms “intermittent” or “intermittently”as used herein means stopping and starting at either regular or irregular intervals. For example, intermittent administration can be administration one to six days per week or it may mean administration in cycles (e.g., daily administration for two to eight consecutive weeks, then a rest period with no administration for up to one week) or it may mean administration on alternate days. The effectiveness of said composition, pharmaceutical composition or medicament could enable a shortened period of treatment with superior results.

[0120] It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0121] Although the at least one compound of any of formulae (I) or 1-38, or the composition, pharmaceutical composition or medicament comprising at least one compound of any of formulae (I) or 1-38 may be administered as the single therapeutic agent, combination therapy including co-administration with one or more additional agents is within the scope of the present invention.

[0122] In some embodiments, the at least one compound of any of formulae (I) or 1-38, or the composition, pharmaceutical composition or medicament, as described herein, is to be administered as sole therapeutic agent. In some embodiments, the at least one compound of any of formulae (I) or 1-38, or the composition, pharmaceutical composition or medicament, as described herein, is not to be administered in combination with any other cannabinoid.

[0123] In some embodiments, the at least one compound of any of formulae (I) or 1-38, or the composition, pharmaceutical composition or medicament, as described herein, is to be administered before, concomitantly with or after at least another therapeutic agent, such as, for example, a cannabinoid.

[0124] Co-administration of at least one compound of any of formulae (I) or 1-38 with one or more therapeutic agents may take place sequentially in any order, simultaneously or a combination thereof. For example, administration of at least one compound of any of formulae (I) or 1-38 can take place prior to, after or at the same time as the administration of the additional therapeutic agent(s). For example, a total treatment period can be decided for the at least one compound of any of formulae (I) or 1-38. The additional agent(s) can be administered prior to the onset of treatment with the at least one compound of any of formulae (I) or 1-38 or following treatment with the at least one compound of any of formulae (I) or 1-38. In addition, the additional agent(s) can be administered during the period of administering the at least one compound of any of formulae (I) or 1-38 but does not need to occur over the entire treatment period. In another embodiment, the treatment regimen includes pre-treatment with one agent, followed by the addition of the other agent or agents. Alternating sequences of administration are also contemplated.

[0125] Alternating administration includes administration of at least one compound of any of formulae (I) or 1-38 or preferably at least one compound of formula (I) is selected from compounds 1, 2, 3, 4, 7, 12 and 38, followed by the additional agent, followed by at least one compound of any of formulae (I) or 1-38, preferably at least one compound of formula (I) selected from compounds 1, 2, 3, 4, 7, 12 and 38 etc. The aforementioned sequences can also be administered in several cycles wherein each cycle may be similar or different with each possibility representing a separate embodiment. In some embodiments, the therapeutic efficacy of the combination of at least one compound of any of formulae (I) or 1-38 and the additional agent(s) is additive. In some embodiments, the therapeutic efficacy is synergistic, namely the overall dose of each of the components may be lower, thus resulting in significantly lower side effects experienced by the subject, while a sufficient desirable therapeutic effect is nonetheless achieved. When combination therapy is involved, the at least one compound of any of formulae (I) or 1-38, preferably at least one compound of formula (I) selected from compounds 1, 2, 3, 4, 7, 12 and 38 and the additional therapeutic agent(s) may be provided in a single dosage form such as a fixed dose combination or in separate compositions intended for simultaneous administration.

[0126] The one or more additional therapeutic agents include, but are not limited to, cannabinoids, terpenes, terpenoids, flavonoids, oils, nitrogenous compounds, amino acids, proteins, glycoproteins, sugars, hydrocarbons, fatty acids, esters, lactones, steroids, non-cannabinoid phenols, and a mixture or combination thereof.

[0127] In some embodiments, the at least one compound of any of formulae (I) or 1-38 or the composition, pharmaceutical composition or medicament as described herein is administered in combination with at least one cannabinoid.

[0128] Exemplary cannabinoids that can be used in the combination therapy include, but are not limited to, cannabidivarinic acid (CBDVA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), tetrahydrocannabinol (THC), cannabichromene (CBC), cannabichromenic acid (CBCA), tetrahydrocannabinolic acid (THCA), cannabicitran, tetrahydrocannabivarin (THCV), cannabigerol (CBG), sesquicannabigerol (sesqui-CBG), sesquicannabigerolic acid (sesqui-CBGA), CBGA-C4, CBG-C4, cannabigerovarinic acid (CBGVA), cannabigerivarin (CBGV), cannabigerorcinic acid (CBGOA), cannabigerorcin (CBGO), cannabigerolic acid monomethyl ether (CBGMA), cannabigerol monomethyl ether (CBGM), cannabicyclol (CBL), cannabicyclolic acid (CBLA), THCA-C4, THC-C4, carboxylic acid (THCV A), tetrahydrocannabivarin (THCV), tetrahydrocannabiorcolic acid (THCOA), tetrahydrocannabiorcol (THCO), THCMA, THCM, CBDA-C4, CBD- C4, cannabidiorcolic acid (CBDOA), cannabidiorcol (CBDO), cannabidiolic acid monomethyl ether (CBDMA), cannabidiol monomethylether (CBDM), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabiorchromenic acid (CBCOA), cannabiorchromene (CBCO), cannabinolic acid (CBNA), cannabinol-C4 (CBN-C4), cannabivarinic acid (CBNVA), cannabivarin (CBNV), cannabiorcolic acid (CBNOA), cannabiorcol (CBNO), CBNA-8-OH, CBN-8-OH, cannabinol methylether (CBNM), cannabielsoin acid (CBEA), cannabielsoin (CBE), cannabielsoic acid (CBEVA), cannabielsoin (CBEV), cannabinodiolic acid (CBNDA), cannabinodiol (CBND), cannabinodivarinic acid (CBNDVA), (-)-A8-trans-tetrahydrocannabinol (A8-THC),cannabitriol-1 (CBT-1), CBT-2, CBT-3, CBTA-1, CBTA-3, cannabitriolvarin (CBTV), CBTV-3, epicannabidiol, and a mixture or combination thereof.

[0129] In some embodiments, the at least one compound of any of formulae (I) or 1-38 or the composition, pharmaceutical composition or medicament as described herein is administered in combination with cannabidiol (CBD). In some embodiments, the at least one compound of any of formulae (I) or 1-38 or the composition, pharmaceutical composition or medicament as described herein is administered in combination with tetrahydrocannabinol (THC). In some embodiments, the at least one compound of any of formulae (I) or 1-38 or the composition, pharmaceutical composition or medicament as described herein is administered in combination with at least another compound of any of formulae (I) or 1-38, or the compounds of formula (I) selected from compounds 1, 2, 3, 4, 7, 12 and 38.

[0130] When the at least one compound as described herein is co-administered with at least one cannabinoid, typical ratios of the at least one compound of any of formulae (I) or 1-38 as described herein and the at least one cannabinoid include, but are not limited to, about 1:1,000 to about 1,000:1, including all iterations of ratios within the specified range. Exemplary ratios include, but are not limited to, about 1:1,000, about 1:900, about 1:800, about 1:700, about 1:600, about 1:500, about 1:400, about 1:300, about 1:200, about 1:100, about 1:75: about 1:50, about 1:40, about 1:30, about 1:20, about 1:15, about 1:10, about 1:5, about 1:2, about 1:1, about 2:1, about 5:1, about 10:1, about 15:1, about 20:1, about 30:1, about 40:1, about 50:1, about 75:1, about 100:1, about 200:1, about 300:1, about 400:1, about 500:1, about 600:1, about 700:1, about 800:1, about 900:1, or about 1,000:1.BRIEF DESCRIPTION OF THE DRAWINGS

[0131] Fig. 1A-B. relates to Anxiety Testing-Open Field Test. A: The scheme represents a mouse in the testing-open field test. B: The graph shows the time in margins (in sec) with respect to the time in arena (in minutes). Mice that received Compound 38exhibited less anxiety-like behavior, spending less time in the margins of the arena compared to the control group which received the placebo.

[0132] Fig. 2 A-B. relates to Anxiety Testing-Elevated Zero Maze. A: The scheme represents a mouse in the Elevated Zero Maze test. B: The graph shows the time in open arms (in sec) for mice which received the placebo and mice which received compound 38. Mice that received Compound 38 exhibited less anxiety-like behavior, spending more time in the open arms of the maze, as compared to the control group which received the placebo.

[0133] Fig. 3 A-B. relates to Social Testing-3-Chambers test. A: The scheme represents a mouse in the middle-chamber of the 3 Chambers test, with an object in the right side-chamber, and another mouse in the left side-chamber. B:The graph shows the time in proximity (in sec) of an object or of another mouse for mice which received Compound 38, or mice which received the placebo, as indicated. Mice that received Compound 38 exhibited more social behavior, spending more time interacting with the other mouse than with an object.

[0134] Fig. 4 A-B. relates to Motor Skills testing - Rotarod test. A: The scheme represents the motor skills testing principle. B: The graph shows the latency to fall (in sec) depending on the trial number, for mice which received Compound 38, as compared to mice which received the placebo. While the Rotarod motor test did not show a significant effect, there was a slight impairment in motor skills initially observed in mice which received Compound 38. However, after three trials, mice which received Compound 38 showed similar results as the control group which received the placebo, indicating that any motor impairment was not permanent.

[0135] Fig. 5 is a graph showing the average weight of the mice in the placebo group and in the group receiving compound 38 as indicated, through the injection protocol. Linear regression showed no significant difference between the slop lines.

[0136] Fig. 6A-D is a combination of graphs showing the results of the open field test. Fig. 6A represents the total time spent in the margins for mice of the placebo group and mice receiving compound 38, as indicated. Fig. 6B represents the latency to first centerentrance for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 6C represents the total time spent in margins between 0 and 40 minutes for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 6D represents the time spent in the margins by 5-minutes time bins between 0 and 40 minutes of test for mice receiving the placebo and mice receiving compound 38, as indicated. P>0.05 - non significant.

[0137] Fig. 7 is a graph showing the results of the elevated zero maze test. Time spent in the open arms of the maze is represented for mice receiving the placebo and mice receiving compound 38, as indicated. P<0.01.

[0138] Fig. 8A-E is a combination of graphs showing the results of the social behavior three chamber test. Fig. 8A shows the social index between mouse and object measured in the 2ndphase of the 3 -chamber test for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 8B shows the time spent in proximity to the object or the mouse in the 2ndphase of the 3-chamber test for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 8C shows the novelty index between novel and familiar mouse measured in the 3rdphase of the 3-chamber test for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 8D shows the time spent in proximity of the familiar mouse or the novel mouse in the 3rdphase of the 3-chamber test for mice receiving the placebo and mice receiving compound 38, as indicated. Fig. 8E shows the total time interacting with a mouse (novel and familiar) measured in the 3rdphase of the 3-chamber test for mice receiving the placebo and mice receiving compound 38, as indicated.

[0139] Fig. 9 is a graph showing the results of the rotarod motor testing. Latency to fall measured at trial 1, trial 2 and trial 3 is represented for mice receiving the placebo and mice receiving compound 38, as indicated.EXAMPLES

[0140] The present invention is further illustrated by the following examples.Example 1: Compound synthesisPreparation of a compound of formula 1

[0141] A compound of formula 1 was prepared according to the following scheme:

[0142] In particular, l,3-benzelenediol,5-hexyl (780 mg, 4 mmol), cis-p-menth-2-ene- 1,8-diol (680 mg, 4 mmol) and p-TSA (25 mg, 4% eq) in DCM (27 ml) were stirred for 24 hr at RT under inert atmosphere. The reaction mixture was diluted with DCM (20 ml) and washed with 0.5N NaOH (20 ml), IN HC1 (20 ml), and brine. An organic solution was separated, dried over sodium sulfate and the solvent was evaporated to dryness to give 970 mg of the crude product. Purification of the crude product was performed by flash column chromatography to give 526 mg of the compound.Preparation of a compound of formula 2

[0143] A compound of formula 2 was prepared according to the following scheme:

[0144] In particular, a solution of 2-[6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en- l-yl]-5-pentylbenzene-l,3-diol (166 mg, 0.5 mmol), ammonium formate (320 mg) and10% Pd / C (20 mg) in methanol (3 ml) was stirred for 2 days at RT. The reaction mixture was added to water (50 ml) followed by the addition of IN HC1 to a pH of 1-2. The crude product was extracted with TBME (30 ml). The crude product (180 mg) was purified by flash column chromatography to give 63 mg of a mixture of the a and [3-Me isomers (33 / 66%).

[0145] Alternatively, 2-[6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en-l-yl]-5- pentylbenzene- 1,3 -diol (0.5g, 1.5 mmol) was dissolved in ethanol (5 ml) and 10% Pd / C (50 mg) was introduced under inert atmosphere. Hydrogen (gas) was babbled into the reaction mixture for 2-3 hr at RT. The reaction mixture was filtered and ethanol was evaporated to dryness to give 0.5 g of a semi solid product.of formula 3

[0146] A compound of formula 3 was prepared from cannabidivarin (CBDV) according to the following scheme:

[0147] In particular, CBDV (1.0 g, 3.5 mmol) was stirred in a mixture of ethanol:water:37% HC1 (65:25:10 v / v, 10 ml) for 3 hr at RT. A product was extracted with hexane (20 ml x 2). The organic phase was separated, washed with water (20 ml) and dried over sodium sulfate. The product was separated by flash column chromatography to give 50 mg of a white solid.

[0148] 1H NMR (400 MHz, CDC13) 66.48 (1 H), 6.26-6.30 (2 H, Ar), 5.67 (1 H, C=CH), 3.84 (1 H), 2.43 (2 H, CH2), 2.08-2.11 (2 H), 1.88-1.91 (3 H), 1.80 (3 H, Me), 1.68-17.3 (1 H), 1.56-1.62 (2 H), 1.27 (1 H), 1.24 (6 H, 2 Me), 0.91 (3 H, Me).of formula 4

[0149] A compound of formula 4 was prepared according to the following scheme:

[0150] In particular, l,3-benzelenediol,5-heptyl (832 mg, 4 mmol), cis-p-menth-2-ene- 1,8-diol (680 mg, 4 mmol) and p-TSA (25 mg, 4% eq) in DCM (27 ml) were stirred for 24 hr at RT under inert atmosphere. The reaction mixture was diluted with DCM (20 ml) and washed with 0.5N NaOH (20 ml), IN HC1 (20 ml), and brine. An organic solution was separated, dried over sodium sulfate and the solvent was evaporated to dryness to give 990 mg of the crude product. Purification of the crude product was performed by flash column chromatography to give 550 mg of the compound.of formula 7

[0151] A compound of formula 7 was prepared according to the following scheme:

[0152] In particular, 5-(l,l-dimethylheptyl)-resorcinol (710 mg, 3 mmol), cis-p-menth- 2-ene-l,8-diol (510 mg, 3 mmol) and p-TSA (25 mg, 4% eq) in DCM (25 ml) were stirred for 24 hr at RT under inert atmosphere. The reaction mixture was diluted with DCM (20 ml) and washed with 0.5N NaOH (20 ml), IN HC1 (20 ml) and brine. An organic solution was separated, dried over sodium sulfate and the solvent was evaporated to dryness to give 1,300 mg of the crude product. Purification of the crude product was performed by flash column chromatography to give 600 mg of the compound.Preparation of a compound of formula 11

[0153] A compound of formula 11 was prepared according to the following scheme:

[0154] In particular, a solution of 2-[6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en- 1-yl]- 5 -pentylbenzene- 1,3 -diol (0.7 g, 2.1 mmol) in 2.0 M solution magnesium methyl carbonate in DMF (2M MMC, 10 ml) was heated for 1 hr at 125 °C under inert atmosphere. The reaction mixture was cooled to 50-60°C and diluted with toluene (20 ml). The solution was slowly added to cold IN HC1 (50 ml) with effective stirring and the two phases mixture was stirred for 15-20 min. The organic phase was separated and washed with water (20 ml). The product was extracted with IN NaOH (25 ml x 2). The water phase was separated and 37% HC1 was added dropwise to pH=l-2. The product was extracted with TBME (25 ml x 2). The organic phase was washed with water and dried over sodium sulfate. The product was purified by flash column chromatography to give 240 mg of an off-white solid.

[0155] 1H NMR (400 MHz, CDC13) 66.23 (1 H, Ar), 5.56 (1 H, C=CH), 4.06 (1 H), 2.7,2.8 (2 H), 2.11 (2 H), 1.91 (2 H), 1.8 (3 H, Me), 1.46-1.66 (4 H), 1.25 (6 H), 0.86 (3 H, Me).Preparation of a compound of formula 12

[0156] A compound of formula 12 was prepared from a compound of formula 11 according to the following scheme:

[0157] In particular, a compound of formula 11 (300 mg, 0.8 mmol) was dissolved in methanol and l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (150 mg) was added. The reaction mixture was stirred for 1 hr at RT under inert atmosphere and methanol was evaporated to dryness. The residue oil was dissolved in a mixture of water (20 ml) and MTBE (30 ml). The organic phase was separated, dried over sodium sulfate and evaporated to dryness. The crude product was purified by flash column chromatography to give 330 mg of a white solid.

[0158] ’ H NMR (400 MHz, CDC13) 6 6.25 (1H, Ar), 5.44 (1H, C=CH), 4.1 (1 H), 3.91 (3 H, CH3-O-), 2.71-2.81 (2 H), 2.11 (2 H), 1.98 (1 H), 1.91 (1 H), 1.77 (3 H, Me), 1.56 (1 H), 1.50 (2 H), 1.33 (4 H), 1.16-1.21 (6 H, 2Me), 0.9 (3 H, Me). Preparation of a compound of formula 13

[0159] A compound of formula 13 was prepared from a compound of formula 11 according to the following scheme:

[0160] In particular, a compound of formula 11 (100 mg, 0.3 mmol) was dissolved in THF (1.5 ml) and carbonyldiimidazole (CDI) (105 mg, 0.64 mmol) was added. The reaction mixture was stirred for 1 hr at 47°C and N,N-dimethylethylene- diamine (80 mg, 0.9 mmol) was introduced. The solution was stirred for 18 hr at 47°C. The reaction mixture was washed with brine (5 ml) and the product was extracted with MTBE (5 ml). The organic phase was separated, dried over sodium sulfate and the solvent was evaporated to dryness to give 90 mg of the crude product. The crude product was purified by flash column chromatography to give 39 mg of a white semi-solid product.Preparation of a compound of formula 14

[0161] A compound of formula 14 was prepared from a compound of formula 11 according to the following scheme:

[0162] In particular, a compound of formula 11 (120 mg, 0.32 mmol) was dissolved in THF (1.5 ml) and carbonyldiimidazole (CDI) (105 mg, 0.64 mmol) was added. The reaction mixture was stirred for 1 hr at 47°C and 3-morpholinpropyl- amine (140 mg, 0.96 mmol) was introduced. The solution was stirred for 2 hr at 47°C. The reaction mixture was washed with brine (5 ml) and the product was extracted with MTBE (5 ml). The organic phase was separated, dried over sodium sulfate and the solvent was evaporated to dryness to give 100 mg of the crude product. The crude product was purified by flash column chromatography to give 39 mg of a white semi- solid product.Preparation of a compound of formula 17

[0163] A compound of formula 17 was prepared in several steps. First, a solution of 2- [6-(2-hydroxypropan-2-y l)-3 -methylcyclohex-2-en- 1 -yl] -5-pentylbenzene- 1 ,3 -diol (1.4g, 4.2 mmol) in pyridine (10 ml) was prepared and acetic anhydride (2 ml) was added. The solution was stirred for 3 days at RT under inert atmosphere. The reaction mixture was then diluted with 1 N HC1 (100 ml), and the product was extracted with TBME (50 ml x 2). The organic layer was separated, washed with water, and dried over sodium sulfate. The suspension was filtered and the solvent was evaporated to dryness to give 2.0 g (100 %) of the triacetylated compound:

[0164] The triacetylated compound (2.0 g) was then dissolved in a mixture of acetic acid (8.5 ml) and acetic anhydride (4.25 ml) followed by the addition of potassium dichromate (2.2 g). The reaction mixture was stirred for 24 hr at 38 °C (bath) and diluted with water(200 ml). The product was extracted with TBME (50 ml x 3). The organic layer was separated, washed with brine (50 ml), and dried over sodium sulfate. The suspension was filtered and the solvent was evaporated to dryness to give 1.2 g (60 %) of the triacetylated keto product. The product was separated to three fractions A (200 mg), B (350 mg), and C (67 mg) by flash column chromatography. Fraction B was used in the subsequent step.

[0165] Finally, the triacetylated keto product (fraction B, 350 mg) was dissolved in MeOH (9 ml) and sodium borohydride (0.3 g) was added in portions at 0-5 °C under inert atmosphere. The reaction mixture was stirred for 24 hr and added to brine (50 ml). 1 NHC1 was added to a pH of 1-2 and the product (compound 17) was extracted with TBME (10 ml x 3). The organic layer was separated, washed with brine (20 ml), and dried over sodium sulfate. The suspension was filtered and the solvent was evaporated to dryness to give 0.32 g of compound 17.

[0166] ’ H NMR (500MHz, CDC13) 6 6.26 (2H, Ar), 5.50 (1 H, C=CH), 4.33 (1 H, CH),3.99 (1H, CH), 2.43 (2 H), 2.30 (1H, CH2), 1.86 (3H, CH3), 1.64 (1H, CH2), 2.11 (1H, CH), 1.55 (2H, CH2), 1.29-1.30 (4 H), 1.26 (3H, CH3), 1.18 (3H, CH3), 0.87 (3 H, Me).Preparation of a compound of formula 30

[0167] A compound of formula 30 was prepared according to the following scheme:

[0168] In particular, a solution of 2-[6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en- 1-yl]- 5 -pentylbenzene- 1,3 -diol (0.332 g, 1 mmol) and 1 -fluor-pyridinium triflate (0.272 g, 1.1 mmol) in DCM (13 ml) was stirred for 18 hr at RT under inert atmosphere. The reaction mixture was diluted with DCM (10 ml) and the organic phase was washed with a solution of 5% sodium bicarbonate in water (20 ml). The organic phase was separated, and the solvent was evaporated to dryness. A crude product was purified by flash column chromatography to give 207 mg of a mixture of the starting material with mono-fluor anddi-fluor derivatives. This mixture was separated by HPLC preparative.

[0169] ’ H NMR (400 MHz, CDCI3) 6 6.22, (1 H, Ar), 5.56 (1 H, C=CH), 3.88 (1 H), 2.52 (2 H), 2.14, 2.09 (2 H), 1.98, 1.66 (2 H), 1.80 (3 H, Me), 1.93 (1 H), 1.57 (2 H), 1.32 (4 H), 1.22 (6 H, 2Me), 0.88 (3 H, Me).Preparation of a compound of formula 37

[0170] A compound of formula 37 was prepared according to the following scheme:

[0171] In particular, 2-[6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en-l-yl]-5- pentylbenzene- 1,3 -diol (94 mg, 0.25 mmol) was dissolved in CD3OD and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide (EDC) (60 mg) was added. The reaction mixture was stirred overnight at RT under inert atmosphere and CD3OD was evaporated to dryness. A residue oil was dissolved in a mixture of water (10 ml) and MTBE (3 ml). The organic phase was separated, dried over sodium sulfate and evaporated to dryness. A crude product was purified by flash column chromatography to give 70 mg of a white solid.Example 2: Shank3 mouse modelMaterials and MethodsMouse model

[0172] Homozygous InsG3680 (+ / +) Shank3 mutant mice, model of autism spectrum disorder, were used. The InsG3680 Shank3 knock-in allele (Shank3*InsG3680) harbors the autism spectrum disorder (ASD)-associated InsG3680 mutation. Homozygous mice lack expression of major SHANK3 protein isoforms; resulting in synaptic and behavioral characteristics similar to human ASD, in both juvenile and adult. Only male Homozygousoffspring were used in the experiment.Animals

[0173] All mice were maintained in 12-h-light / 12-h-dark conditions with ad libitum access to food and water. All mice were one-month old when the experiment started. The animals were weighed once a week for the entire experimental period. Animals were allocated to groups randomly.Tested compound

[0174] Compound 38, also referred to as 331-18A, or the placebo were administered to mice daily for 5 days a week at a concentration of 20 mg / kg, by subcutaneous (s.c.) injection into the scruff of the mice necks over the course of 30 day. Compound 38 was compared to a placebo. One dose of compound or placebo was administered subcutaneously (s.c.), 5 days per week for 30 days, from the age of one month. 12 mice were tested per group. Two groups of mice were studied: the group of model mice that received Compound 38 (331-18A), versus the group of model mice that received the placebo.Anxiety TestingOpen Field Exploration Test

[0175] The test involves placing a mouse in a large, empty arena (see Figure 1A) for a duration of one hour and then measuring its movement and behavior. Motor activity and exploration behaviors were recorded on video. Anxious mice tend to stay close to the edges of the arena and avoid the center. Using a statistical software, the time spent in the margins of the arena can be measured.Elevated zero maze

[0176] Mice were placed in a circular platform with two open and two closed sections (see Figure 2A). Mice were initially placed in one of the closed sections of the maze and allowed to explore for 5 minutes. The movements of the mice between the sections werevideotaped, and the time spent in the open arms was measured. Mice that showed extremely anxious behavior (i.e., less than 5 seconds outside of the closed arms) were disqualified. The experiment measures the amount of time the animal spends in the open versus closed sections to assess anxiety levels. Anxious mice tend to stay close to the closed sections and avoid the open sections. By using statistical software, the time spent in the open sections (open arms) can be measured. Elevated plus maze test was performed to assess anxiety related behavior.Behavioral testsThree chambers - Social preference test

[0177] This test allows to assess the social behavior of mice. Mice were placed in the middle chamber of three interconnected chambers (see Figure 3A). The experiment contains three phases. For the first phase, referred to as habituation phase, both side chambers were empty, the test mouse was placed in the middle chamber and allowed to explore all three chambers for 15 minutes. For the second phase, referred to as sociability phase, one side chamber contained an object, while the second side chamber contained a stranger mouse, the test mouse was placed in the middle chamber and allowed to explore all three chambers for 15 minutes. In the third phase, referred to as social novelty phase, one of the side chambers contained a familiar mouse and the second side chamber contained a stranger mouse, the test mouse was placed in the middle chamber and allowed to explore all three chambers for 15 minutes. The position of the object and stranger mouse was switched between trials to eliminate any potential place preference. Each stimulation mouse was used only twice a day. Mice which showed extremely irregular behavior (i.e., spent no time in proximity to other mice, freezing) were removed from analysis. The experiment consisted in measuring the amount of time the tested mouse spent interacting with the object (placed in one chamber) or with a stranger mouse (placed in another chamber), as well as the amount of time spent with the familiar mouse (placed in one chamber) or with the stranger mouse (placed in another chamber). Mice that are more social tend to spend more time interacting with another mouse, while less social mice will spend more time interacting with the object.Motor Skills testing - Rotarod test

[0178] The test involves placing the mouse on a rotating rod (see Figure 4A) that gradually increases in speed, and measuring how long the mouse can remain on the rod. The rotating rod was initially maintained at a constant speed of 4 revolutions per minute (rpm). After ensuring proper body orientation and placement on the rod, the speed was gradually increased to 40 rpm within a 3-minute time frame. This test is frequently used in research to assess neurological disorders. This test measures mice motor coordination and balance. To prevent the mice from grasping the rod and hanging onto it instead of walking, 3D printed adapters were used to double the diameter of the rod from 15 cm to 30 cm. Mice that either clung to the rod for at least 2 full rotations or fell off within the first 10 seconds of each trial were disqualified, and their performance was not considered in the analysis. Each mouse underwent three trials on the same day, with a one-hour break between trials. Mice which jumped from the apparatus more than once were removed from the test.Statistical analysis

[0179] Results are expressed as means ± standard error mean (SEM) calculated using GraphPad Prism 9.4.1 for Windows (GraphPad Software, San Diego, CA, USA). Statistical analysis was performed using various statistical tests, including Student’s t test for the direct comparison between two groups, 2-way repeated measured ANOVA, mixed-effects analysis. Significance level of p < 0.05 was considered statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.0005, **** p < 0.0001). The normality of distributions and equality of variances were assessed, and appropriate statistical analyses were applied accordingly. Outliers were identified using the Grubbs method (p < 0.05).Preliminary Results

[0180] Preliminary results were obtained from 5-6 subjects per group.

[0181] In the Open test field (Figures 1A and IB), mice which received Compound 38 spent less time in the edges of the arena, as compared to mice from the control group (which received the placebo). These results indicate that mice which received Compound38 decreased their anxiety level.

[0182] In the Elevated Zero Maze test (Figures 2A and 2B), mice which received Compound 38 spent significantly more time in the open part of the maze, with a Time in Open Arms (in second) of about 35 sec, as compared to mice which received the placebo, which spent about 18 sec in the Open Arms of about 18 sec in the control group, the difference being statistically significant (p=0,0325 t-test).

[0183] In the three chambers test (Figures 3A and 3B), it was observed that mice which received Compound 38 were spending significantly more time with the other animal than with the object, as compared to mice which received the placebo which were spending significantly more time with the object than with the other mouse. The difference between active and control group is statistically significant (p=0,0044 ANOVA).

[0184] The Motor Skills testing - Rotarod test (Figures 4A and 4B) demonstrates that after three trials, mice which received Compound 38 showed similar results as the control group which received the placebo, indicating that any motor impairment was not permanent.Results

[0185] Complete results were obtained from the entire cohort (z.e., 12 mice in each group).

[0186] As shown on Figure 5, the average weight of the mice remained consistent throughout the injection protocol. In particular, no significant difference in the average weight was observed between mice receiving the placebo and mice receiving compound 38 (Figure 5). These results indicate that compound 38 did not induce any significant adverse side effects, and did not negatively affect the mice development and growth.

[0187] Figures 6A-D show the results of the open-field test. While there was no significant difference in the total time spent in the margins between mice receiving compound 38 as compared to mice receiving the placebo (Figure 6A), an overall trend could be observed, in which mice receiving compound 38 tend to spend less time in the arena margins (between 5% to 7%), as compared to mice receiving the placebo, especiallybetween 0-40 minutes of test (Figure 6C). No significant difference regarding the time of first entry to the center of the arena could be observed between mice receiving the placebo and mice receiving compound 38 (Figure 6B). Finally, considering the time spent in the margins by 5-minute time bins between 0 to 40 minutes (Figure 6D), no significant difference could be observed, although there is a trend for mice receiving compound 38 to spend less time in the margins of the arena as compared to mice receiving the placebo.

[0188] Figure 7 shows the results of the elevated zero maze test. Mice receiving compound 38 spent significantly more time (p = 0.0088) in the open arms of the elevated zero maze, as compared to mice receiving the placebo (Figure 7). Indeed, mice receiving compound 38 spent almost 200% more time in the open arms of the elevated zero maze, as compared to mice receiving the placebo (Figure 7). These results suggest that mice receiving compound 38 have decreased levels of anxiety, as compared to mice receiving the placebo.

[0189] Figures 8A-E show the results of the three chambers - social preference test. During the second phase of the test, i.e., the sociability phase, no significant difference was observed in the social index between mice receiving compound 38 and mice receiving the placebo (Figure 8A), with a high variability in the scoring and a slight preference for the mouse rather than the object in the group of mice receiving the placebo. However, when looking at raw time spent in proximity of the mouse or the object, a strong and significant preference for the mouse was observed in both mice receiving compound 38 and mice receiving the placebo (Figure 8B). During the third phase of the test, i.e., the social novelty phase, a slight preference for the novel mouse (around 68%) was observed for mice receiving compound 38, as compared to mice receiving the placebo, however not significant (Figure 8C). When looking at raw time spent in proximity of the familiar mouse or the novel mouse, both mice receiving compound 38 and mice receiving the placebo exhibited a slight preference towards the novel mouse, however not significant (Figure 8D). Finally, when looking at the total interaction time with either familiar or novel mouse, no significant difference was observed between mice receiving compound 38 and mice receiving the placebo (Figure 8E). These results demonstrate thatcompound 38 does not affect the social behavior of the treated mice.

[0190] Figure 9 shows the results of the motor skill - rotarod test. No significant difference was observed between mice receiving compound 38 and mice receiving the placebo, with a high in-group variability. These results demonstrate that compound 38 does not affect the motor skills of the treated mice.Conclusion

[0191] All together, these results show that compound 38 does not induce adverse side effects, and in particular, does not affect the development ( / '.<?., weight), of the treated mice, as compared to mice receiving the placebo. In addition, compound 38 does not negatively impact the social behavior, and the motor skills of the treated mice, while strongly and significantly decreasing the anxiety levels, as compared to mice receiving the placebo.

Claims

CLAIMS1. A compound of formula (I):or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof, whereinR1is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;R2is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, cyano, heterocyclyl, O-heterocyclyl, amino, or amido;R3is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, alkoxy, aryloxy, amino, amido, or C(O)ORawherein Rais H, deuterium, or C1-C4 alkyl;R4is H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, or unsubstituted C(O)Ci-C4alkyl;R5is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, or C(O)ORbwherein Rbis H, deuterium, or C1-C4 alkyl; and the dotted line represents an optional second carbon-carbon bond, wherein each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated, for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders, such as behavior / impairments associated with autism; attention deficit with and without hyperactivity disorder associated with autism and intellectual disability associated with autism.

2. The compound for use according to claim 1, wherein the compound of formula (I) is selected from compounds 1-38 delineated in Table A and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:[Table A]The compound for use according to any one of claims 1 or 2, wherein the compound of formula (I) is selected from compounds 1, 2, 3, 4, 7, 12 and 38, delineated in Table B and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:

4. The compound for use according to any one of claims 1 to 3, wherein the compound of formula (I) is compound 38 of formula:(Compound 38) or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof.

5. A pharmaceutical composition comprising a compound of formula (I):or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof, whereinR1is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;R2is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, cyano, heterocyclyl, O-heterocyclyl, amino, or amido;R3is H, deuterium, hydroxyl, halogen, haloalkyl, nitro, alkoxy, aryloxy, amino, amido, or C(O)ORawherein Rais H, deuterium, or C1-C4 alkyl;R4is H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, or unsubstituted C(O)Ci-C4alkyl;R5is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, or C(O)ORbwherein Rbis H, deuterium, or C1-C4 alkyl; and the dotted line represents an optional second carbon-carbon bond, wherein each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated,and a pharmaceutical acceptable carrier or excipient, for use in the treatment of autism spectrum disorder (ASD) and / or associated disorders, such as behavior / impairments associated with autism; attention deficit with and without hyperactivity disorder associated with autism and intellectual disability associated with autism.

6. The pharmaceutical composition for use according to claim 5, wherein the compound of formula (I) is selected from compounds 1-38 delineated in Table A and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:

7. The pharmaceutical composition for use according to any one of claims 5 or 6, wherein the compound of formula (I) is selected from compounds 1, 2, 3, 4, 7, 12 and 38, delineated in Table B and salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, and mixtures thereof:[Table B]8. The pharmaceutical composition for use according to any one of claims 5 to 7, wherein the compound of formula (I) is compound 38 of formula:or a salt, hydrate, solvate, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer, and mixture thereof.

9. The compound for use according to any one of claims 1 to 4 or the pharmaceutical composition for use according to any one of claims 5 to 8, wherein the treatment of ASD corresponds to the treatment of anxiety and / or inappropriate social interactions.

10. The compound for use according to any one of claims 1 to 4 or the pharmaceutical composition for use according to any one of claims 5 to 9, wherein the associated disorders are selected from behavior / impairments associated with autism, attention deficit with and without hyperactivity disorder associated with autism and / or intellectual disability associated with autism.

Citation Information

Patent Citations

  • A method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of transdelta-9-tetrahydrocannabinol

    EP0494665B1

  • Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol

    US5227537A

  • Compound as well as preparation method and application thereof

    CN115197051A

  • A method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of transdelta-9-tetrahydrocannabinol

    EP0494665A1

  • Cannabidiol derivative, and preparation method therefor and medical use thereof

    EP4089084A1